Departments of Internal Medicine and Physiology & Biophysics, 3181B Medical Education and Biomedical Research Facility, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.
Phone: (319) 335-7604; Fax: (319) 353-5350; E-mail: firstname.lastname@example.org.
First published July 15, 2002 - More info
See the related article beginning on page 229.
The renin-angiotensin system (RAS) has long been recognized as an important regulator of blood pressure and electrolyte balance in mammals. The RAS exerts its effects through the generation and action of angiotensin II (Ang II), which has potent vasoconstrictor, antinatriuretic, and dipsogenic properties.
Ang II is generated by the serial cleavage of angiotensinogen, first by the aspartyl protease renin, and then by the carboxydipeptidase angiotensin converting enzyme (ACE). Ang II acts as both an endocrine hormone and an autocrine and paracrine effector, notably in the kidney, heart, and brain, where it can be synthesized locally. Studies of gene-targeted mice reveal that in addition to having cardiovascular effects, the RAS is required during development, in particular during the postnatal period as development of the kidney continues (1).
Elevated expression of gene products involved in the RAS has been observed in a number of experimental and genetic models of hypertension. Consistent with the view that abnormal RAS regulation underlies at least some forms of hypertension, infusion of Ang II causes an elevation in blood pressure, and inhibitors of the RAS pathway — particularly ACE inhibitors and angiotensin receptor blockers — are effective antihypertensive agents. Because renin acts at the rate-limiting step in Ang II synthesis, considerable attention has been paid to the transcriptional regulation of the Renin gene and to processing and secretion of its product. However, despite over two decades of study, we are only now beginning to understand some of the fundamental mechanisms regulating renin expression.
Undoubtedly, the absence of good models of renin expression has slowed progress in this field, but with the availability of As.4.1, a kidney-derived cell line expressing endogenous renin mRNA (2), the past two to three years have seen significant advances in our understanding of Renin gene regulation. These cells, originally isolated from a tumor in a transgenic mouse expressing an SV40 large T antigen under control of the Renin promoter (2), represent the best available in vitro model for a juxtaglomerular cell. To date, most of what has been learned regarding Renin regulatory sequences is from deletion analysis of the 5′ flanking region of this gene in transiently transfected As4.1 cells.
In this issue of the JCI, Li et al. (3) describe an innovative approach to uncover a potentially important regulatory circuit controlling renin transcription. Building upon clinical observations of an inverse relationship among plasma vitamin D3 (VD3) levels and blood pressure and plasma renin activity (4–6), and on the observation that VD3 supplementation reduces blood pressure in hypertensive patients (7, 8), Li and colleagues hypothesized that vitamin D3 receptor (VDR3) may be a primary negative regulator of renin expression. They therefore examined the levels of renin mRNA in kidneys of VDR null mice and found both renin mRNA and protein were elevated. Moreover, they showed, dietary strontium, an inhibitor of VD3 synthesis, increases renal renin mRNA levels even in normal mice, whereas direct administration of VD3 has the opposite effect. Consistent with these in vivo data, stable transfection of VDR into As4.1 cells results in a VD3-dependent reduction of both endogenous renin mRNA and Renin promoter activity.
Li et al. go to considerable lengths to show that the effects of VD3 and the VDR on renin are not indirect ones, mediated by calcium metabolism or parathyroid hormone (PTH), both of which are known to independently influence renin expression (9, 10). The authors confirm here that VDR–/– mice exhibit a 30% drop in blood ionized calcium and a 150-fold increase in plasma PTH, but they show that dietary intervention to normalize blood calcium and markedly reduce plasma PTH has no effect on renal renin expression in VDR–/– mice. Moreover, they find that renin mRNA is elevated even early in life, before changes in plasma calcium or PTH occur, and that Gcm–/– mice, which lack parathyroid glands and are hypocalcemic, do not have elevated renin mRNA. Finally, Li et al. confirm that As4.1 cells, even when stably transfected with PTH receptor cDNA, do not modulate renin expression in response to PTH.
The VDR is a member of the thyroid hormone (T3) subfamily of nuclear hormone receptor transcription factors, which also includes retinoic acid receptor (RAR) and PPAR. All members of this family heterodimerize with retinoid X receptor (RXR) to form the active transactivator and recognize the cognate sequence AGGTCA-N-AGGTCA. Selectivity in receptor binding is encoded in the number of nucleotides (N) separating the AGGTCA direct repeats (11). Gross and colleagues identified an enhancer of transcription upstream of the Renin gene that is conserved in all three mouse Renin genes and the human RENIN gene (12–14). Within the enhancer lies the reverse complement to the T3R consensus sequence (TGACCT-N-TGACCT) (Figure 1), and this sequence is required for renin enhancer activity in As4.1 cells. Our group has demonstrated that 3-tandem copies of this T3R motif (3XTRE) have the same transactivating activity as the entire enhancer, therefore bypassing the need for the binding of other transcription factors when this element is present in multiple copies (15). Interestingly, as in the current paper, we found that VD3 treatment significantly reduced activity of a transiently transfected Renin promoter-3XTRE–reporter gene in As4.1 cells (15). This clearly defines the TGACCT-N-TGACCT sequence as a potential candidate binding site for VD3/VDR.
Schematic map of the renin enhancer. The location of binding sites (and their original designations Ea–Ee) for transcription factors is shown. Ea stands for enhancer element a and was shown to bind NF-Y. Eb and Ec (enhancer elements b and c) bind to RAR/RXR and may also bind to VDR. Ed binds to the CREB/ATF family of transcription factors, while Ee binds the e-box proteins USF-1 and USF-2.
The regulation of renin transcription is very likely to be complex. The enhancer contains at least five different binding sites for transcription factors, and several of the sequences bind more than one factor (Figure 1). For instance, the putative VDR binding site is also the binding site for RARα/RXRα, and retinoic acid treatment of As4.1 cells stimulates renin expression and renin promoter activity (15). The activity of the RAR/RXR binding site (and consequently the enhancer) may therefore be dependent upon the presence of either the stimulatory ligand (vitamin A) or the inhibitory ligand (vitamin D). Likewise, gel supershift and expression of dominant negative mutants of RAR clearly demonstrate that other, as yet unknown factors bind to this sequence and participate in Renin regulation.
Additional complexities are also present within the enhancer. For example, some of the binding sites are arranged to foster competition between transcription factors. The NF-Y binding site overlaps with the more promoter proximal TGACCT of the RAR response element (RARE), and the negative regulatory activity of NF-Y is dependent on this specific orientation of binding sites because NF-Y physically blocks other stimulatory factors from binding to the RARE (16) (Figure 1). Upstream of the RARE are sequences which bind members of the CREB/ATF family of transcription factors and several E-box transcription factors; mutations in either abolish enhancer activity (17).
In retrospect, given the now-known complexities associated with the “enhancer,” it was probably incorrect to call the sequence an “enhancer” at all. More likely, this sequence is a compound regulatory element with numerous binding specificities and both stimulatory and inhibitory activity. Presumably, transcription factors binding to this sequence must also interact with transcription factors binding near the start site of transcription, such as the proximal promoter element, recently identified to bind HOX:PBX factors, which may help regulate expression of renin in specific cells during development (18). The importance of transcription factors that regulate renin throughout development cannot be overemphasized. Studies in Drosophila and knockout mice have illustrated the profound effects loss of Hox function can have on development. Deficiencies of both vitamin A and vitamin D are likewise highly detrimental systemically (19, 20).
Ultimately, the transcriptional response to physiological cues probably reflects not just the activity of the VDR or other individual transactivators, but rather the interplay among the different regulators that bind the Renin enhancer and promoter. The relevance of the various binding sites must therefore be tested both in vitro and in vivo to determine which transcription factors contribute to known physiological responses. Given the hypotensive effect of VD3 and VD3-mimetics, it will also be crucial, for therapeutic diagnostic purposes, to bring this research full circle and determine the relationship between these and other transcription factors and the regulation of blood pressure.